Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient
US10765720B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 3, 2018 |
| Grant date | Sep 8, 2020 |
| Priority date | — |
| Expiry date | Dec 3, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.